Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK 02/010).-Reference-Cited by-同舟云学术

Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK 02/010).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:4014-4014
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Cunningham David¹,Alderson Derek²,Nankivell Matthew Guy³,Stenning Sally Patricia³,Blazeby Jane M.⁴,Griffin Michael⁵,Crellin Adrian⁶,Grabsch Heike I.⁷,Falk Stephen⁸,Okines Alicia Frances Clare¹,Robb Claire³,Langley Ruth E⁹,

Affiliation:

1. Royal Marsden Hospital, Sutton, United Kingdom

2. Queen Elizabeth Hospital, Birmingham, United Kingdom

3. Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom

4. University of Bristol, Bristol, United Kingdom

5. Royal Victoria Infirmary, Newcastle, United Kingdom

6. St James's Institute of Oncology, St. James's University Hospital, Leeds, United Kingdom

7. Leeds Institute of Cancer Studies and Pathology, University of Leeds, Leeds, United Kingdom

8. Bristol Haematology and Oncology Centre, Bristol, United Kingdom

9. Medical Research Council, Clinical Trials Unit at University College London, London, United Kingdom

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.4014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics;Nature Communications;2018-07-30

2. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus;Gastroenterology;2018-01

3. Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma;Chirurgia;2018

4. Adenocarcinoma of the esophagus: controversies and consensus;Chinese Clinical Oncology;2017-10

5. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma;Journal of Clinical Oncology;2017-02-01